Most people approach a new preparation looking for a signal that is hard to miss — a noticeable change that arrives within a few days and is clearly attributable to what they started taking. That is a reasonable expectation for medications that work through acute mechanisms. It is not a reasonable expectation for cannabinoid preparations that work through the endocannabinoid system, which is a regulatory system operating on timescales of days to weeks, producing changes that are often described as things becoming quieter or more manageable rather than things changing dramatically. The framework for evaluating this kind of response is different from what most people use, and getting it right matters for drawing accurate conclusions about whether something is working.

Start Before You Start

The most useful thing you can do before beginning a cannabinoid preparation is to spend a week noticing the things you are hoping will change — before anything has changed. Not formally, not with a scoring system, but with enough attention that you have an honest baseline.

How does your sleep feel right now? Not in general — this week. Is it taking a long time to fall asleep, or is sleep onset fine but waking in the early hours the problem? How do you feel when you get up? How does your stress feel in the afternoon? What is the quality of your recovery after a physically or emotionally demanding day? How often in a given week does something feel unmanageable?

These are not medical assessments. They are observations. The reason they matter is that without a baseline, people consistently either overcredit or undercredit what changes. A week of unusually good sleep at the start of a trial gets attributed to the preparation when it might have happened anyway. Three weeks of difficult sleep gets attributed to the preparation doing nothing when it might be occurring in a preparation that is otherwise doing something useful. A baseline gives you something to compare against. Without it, you are comparing against a memory, which is unreliable.

What to Watch — and What Not to Watch For

The effects most consistently reported with CBG and CBD preparations, across observational data and clinical research, fall into a specific category: things that were difficult become somewhat less difficult. The edge of stress feels less sharp. Sleep that was interrupted becomes slightly more consolidated. Recovery that was taking three days takes two. Anxiety that was present in specific situations feels more manageable without disappearing.

These are not dramatic effects. They are not the kind of effect that makes a person say "I felt it kick in." They are the kind of effect that a person notices in retrospect — two or three weeks in — when they realise the hard week they just had felt more navigable than a comparable hard week used to feel. That retrospective recognition is often the signal.

What not to watch for: an immediate, noticeable, session-specific effect that is clearly attributable to the preparation. Some people do report this — a sense of calm or shift in the hour after a sublingual dose — and that experience is real and consistent with the pharmacokinetics. But it is not universal, and its absence does not mean the preparation is not working. The ECS does not respond on that timeline for most people. Watching for that kind of acute signal and concluding nothing is happening because it does not arrive is one of the most common reasons people discontinue a preparation that was, in fact, producing a gradual effect they would have noticed if they had stayed with it long enough.

The Timeline That Actually Applies

Week one and two: this is too early to draw conclusions about whether a preparation is working. Placebo effects are most active in this window, which means both positive and negative evaluations in the first two weeks are unreliable. Continue consistently, at the same dose and timing each day, and observe without concluding.

Week three and four: this is when meaningful signal begins to emerge for most people. Not a dramatic shift, but the beginning of a pattern. The retrospective recognition described above — realising things felt somewhat different this week — typically begins here if it is going to happen. This is also when sleep is often the first domain to show change, if change is coming.

Week five and six: if nothing has shifted at all by this point — no change in sleep quality, stress, recovery, or any of the domains you identified before starting — there are three questions worth working through. First, is the dose pharmacologically relevant? The research articles on individual variation and bioavailability explain why the same label dose reaches different plasma concentrations in different people. Second, are there medications involved that could be masking or interfering with the response? The interactions article covers this. Third, is the preparation of sufficient quality to contain what it claims? The integrity problem article covers this.

If all three questions have satisfactory answers and six weeks have passed without any signal, the honest conclusion is that this preparation at this dose is not producing a noticeable effect for you — which is a valid and documented outcome given individual variation, not evidence that cannabinoids do not work in general.

A note on keeping records: even a brief daily note — three or four words — about how you slept, how your stress felt, or how your energy was is worth more than memory when you are trying to evaluate a gradual change over weeks. Not because you need data, but because the mind is not reliable at remembering the texture of ordinary days in sequence. A note made at the time is more honest than a reconstruction from three weeks later. A small notebook kept on the nightstand serves this purpose as well as anything.

When Something Feels Wrong

Occasionally people report effects they did not expect and did not want — nausea, headache, unusual fatigue, or a wired quality that interferes with sleep. These experiences deserve honest investigation rather than either dismissal or alarm.

Nausea occurring within hours of a dose, particularly in someone on antidepressants, is most likely a CYP2D6 interaction causing mild SSRI elevation — not a direct response to the cannabinoid. Unusual fatigue is sometimes a sign that the dose is higher than needed. A wired or activated quality that interferes with sleep occasionally occurs at doses that are too high for the individual and often resolves with dose reduction. Headache in the first week sometimes reflects minor adjustment as the ECS modulates.

None of these experiences are reasons to stop without thinking through the cause. Most of them are reasons to adjust dose, timing, or to have a conversation with a prescribing physician if medications are involved. The responsible use article covers the full framework for managing these situations.